

DAFTAR PUSTAKA

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. *Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries*. *Ca Cancer J Clin*. 2021; 71: 209-49
2. Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Srici F, et al. *Association between common risk factors and molecular subtypes in breast cancer patients*. *The Breast*. 2013; 22: 344-50
3. Kemenkes RI. Infodatin. *Beban Kanker di Indonesia*. Kementerian Kesehatan Republik Indonesia. 2019: 1-16
4. Marpaung MRA, Khambri D, Asterina. *Karakteristik Penderita Kanker Payudara dengan Metastasis Jauh Tunggal di Kota Padang Tahun 2014-2018*. *Jikesi*. 2020; 2(1): 82- 9
5. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: *Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries*. *CA Cancer J Clin*. 2018; 68: 394-424.
6. Yang H, Wang R, Zeng F, Zhao J, Peng S, Ma Y, et al. *Impact of Molecular Subtypes on Metastatic Behavior and Overall Survival in Patients with Metastatic Breast Cancer: A Single- Center Study Combined with a Large Cohort Study Based on The Surveillance, Epidemiology and End Results Database*. 2020; 20(4): 1-11
7. Firdaus VRP, Asri A, Khambri D, Harahap WA. *Hubungan Grading Histopatologi dan Infiltrasi Limfovaskular dengan Subtipe Molekuler pada Kanker Payudara Invasif di Bagian Bedah RSUP. Dr. M. Djamil Padang*. *JKA*. 2016; 5(1): 165-72

8. Soediro R, Nugroho RS, Gondhowiardjo SA, Djoerdan Z, Poetiray EDC. *Karakteristik Subtipe Kanker Payudara Berdasarkan Status Hormonal dan Her-2*. Journal of the Indonesian Radiation Oncology Society. 2010; 1(2): 43-7
9. Mohammed AA. *Prognostic parameter differences in breast cancer patients between luminal A and luminal B types after application of the new classification according to Ki67 score*. Int J Surg Open. 2021; 34: 1-8
10. Chen XS, Ma CD, Wu JY, et al. *Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer*. Tumori 2010;96 (1): 103-110
11. Gong Y, Liu YR, Hu X, Shao ZM. *Impact Of Molecular Subtypes On Metastatic Breast Cancer Patients: a Seer Population-Based Study*. Scientific Reports. 2017: 1-10
12. Abdelkrim SB, Trabelsi A, Missaoui N, et al. *Distribution of molecular breast cancer subtypes among Tunisian women and correlation with histopathological parameters: A study of 194 patients*. Pathol Res Pract 16 [Epub] ahead of print. 2010
13. Kennecke H, Yerushalmi R, Woods R, et al. *Metastatic behavior of breast cancer subtypes*. J Clin Oncol 2010; 28 (20): 3271-3277
14. Xiao W, Zheng S, Yang A, Zhang X, Zou Y, Tang H, et al. *Breast Cancer Subtypes and The Risk of Distant Metastasis at Initial Diagnosis: A Population-Based Study*. Cancer Management and Research. 2018; 10: 5329-38
15. Kementerian Kesehatan Republik Indonesia. *Panduan Penatalaksanaan Kanker Payudara (Breast Cancer Treatment Guideline)*. J Kesehat Masy. 2019;4(4):1-50.

<http://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf>

16. Perhimpunan Ahli Bedah Onkologi Indonesia. *Panduan Penatalaksanaan Kanker 2020*. II. (Djoko H, Haryono S, Arief HW, eds.). PERABOI (Perhimpunan Ahli Bedah Onkologi Indonesia); 2020.
17. Szymiczek A, Lone A, Akbari MR. *Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review*. Clin Genet. 2021;99(5):613–37.
18. Yin L, Duan JJ, Bian XW, Yu SC. *Triple-negative breast cancer molecular subtyping and treatment progress*. Breast Cancer Res. 2020;22(1):1–13.
19. Kobayashi N, Hikichi M, Ushimado K, Sugioka A, Kiriya Y, Kuroda M, et al. *Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival*. Clin Transl Oncol. 2017;19(10):1232–40.
20. Chaffer, C. L. & Weinberg, R. A. *A perspective on cancer cell metastasis*. Science 331, 2011;1559–1564.
21. Lu, X. & Kang, Y. *Organotropism of breast cancer metastasis*. JMammary Gland Biol. Neoplasia 12, 2007; 153–162
22. Liu, Y. & Cao, X. *Characteristics and significance of the pre-metastatic niche* Cancer Cell 30, 2016; 668–681
23. Paget, S. *The distribution of secondary growths in cancer of the breast*. Cancer Metastasis Rev. 8, 1989; 98–101.
24. Wenjing Chen¹, Andrew D. Hoffmann. *Organotropism: new insights into molecular mechanisms of breast cancer metastasis*. Precision Oncology. 2018

25. Wu, Q. et al. *Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study*. *Oncotarget* 8, 2017;27990–27996.
26. Yates, L. R. et al. *Genomic evolution of breast cancer metastasis and relapse*. *Cancer Cell* 32, 2017;169–184 e167.
27. Anjanappa, M. et al. *A system for detecting high impact-low frequency mutations in primary tumors and metastases*. *Oncogene*. 2017; <https://doi.org/10.1038/onc.2017.322>.
28. Hoshino, A. et al. *Tumour exosome integrins determine organotropic metastasis*. *Nature* 527, 2015;329–335.
29. Ma, L., Teruya-Feldstein, J. & Weinberg, R. A. *Tumour invasion and metastasis initiated by microRNA-10b in breast cancer*. *Nature* 449, 2007;682–688.
30. Fong, M. Y. et al. *Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis*. *Nat. Cell Biol.* 17, 2015;183–194.
31. Baccelli, I. et al. *Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay*. *Nat. Biotechnol.* 2013;31, 539–544.
32. Sihto, H. et al. *Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study*. *Breast Cancer Res.* 13, 2011; R87.
33. Gay, L. J. & Felding-Habermann, B. *Contribution of platelets to tumour metastasis*. *Nat. Rev. Cancer* 11, 2011;123–134.
34. Najmeh, S. et al. *Neutrophil extracellular traps sequester circulating tumor cells via beta1-integrin mediated interactions*. *Int. J. Cancer* 140, 2017;2321–2330.

35. Wculek, S. K. & Malanchi, I. *Neutrophils support lung colonization of metastasis initiating breast cancer cells*. *Nature* 528, 2015;413–417.
36. Weilbaecher, K. N., Guise, T. A. & McCauley, L. K. *Cancer to bone: a fatal attraction*. *Nat. Rev. Cancer* 11, 2011;411–425.
37. Awolaran, O., Brooks, S. A. & Lavender, V. *Breast cancer osteomimicry and its role in bone specific metastasis; an integrative, systematic review of preclinical evidence*. *Breast* 30, 2016;156–171.
38. Anborgh, P. H., Mutrie, J. C., Tuck, A. B. & Chambers, A. F. *Role of the metastasis promoting protein osteopontin in the tumour microenvironment*. *J. Cell Mol Med.* 14, 2010; 2037–2044.
39. Bos, P. D. et al. *Genes that mediate breast cancer metastasis to the brain*. *Nature* 459, 2009;1005–1009.
40. Fidler, I. J. *The role of the organ microenvironment in brain metastasis*. *Semin.Cancer Biol.* 21, 2011; 107–112.
41. Blanco, M. A. & Kang, Y. *Signaling pathways in breast cancer metastasis—novel insights from functional genomics*. *Breast Cancer Res.* 13, 2011;206.
42. Gao, H. et al. *The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites*. *Cell* 150, 2012;764–779.
43. Wendel, C. et al. *CXCR4/CXCL12 participate in extravasation of metastasizing breast cancer cells within the liver in a rat model*. *PLoS One* 7, 2012.
44. Hazan, R. B., Phillips, G. R., Qiao, R. F., Norton, L. & Aaronson, S. A. *Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis*. *J. Cell Biol.* 148, 2000;779–790.

45. Asgeirsson, K. S., Olafsdottir, K., Jonasson, J. G. & Ogmundsdottir, H. M. *The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer.* Cytokine 10, 1998; 720–728.
46. Jamnani et al. *Faktor resiko terjadinya metastasis jauh pada kanker payudara.* Radiologi dan Onkologi Indonesia, 2016; 55-59
47. Hasnita et al. *Pengaruh faktor risiko hormonal pada pasien kanker payudara di RSUP.DR.M.Djamil padang.* Jurnal kesehatan andalas, 2019; 8(3)
48. Morchet al. *Contemporary hormonal contraception and the risk of breast cancer.* The new England Journal medicine. 2017 ;377(1):2228-3
49. Elkin ebet al. *The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999.* Cancer. 2005;104(6): 1149–57.
<https://doi.org/10.1002/cncr.21285>.
50. Laura s et al. *Tumour size as a predictor of axillary node metastases in patients with breast cancer.* Anz j surg. 2006; 76(11):1002–6. <https://doi.org/10.1111/j.1445-2197.2006.03918.x>
51. Anwar et al. *Risk factors of distant metastasis after surgery among different breast cancer subtypes: a hospital-based study in Indonesia.* World journal of surgical oncology. 2020 18:117 <https://doi.org/10.1186/s12957-020-01893-w>
52. Qiu y et al. *A multiple breast cancer stem cell model to predict recurrence of t1-3, n0 breast cancer.* BMC cancer. 2019; 19:729. <https://doi.org/10.1186/s12885-019-5941-5>.
53. Yuan et all, *KI-67 expression in luminal type breast cancer and its association with the clinicopathology of the cancer,* Oncology letter, 2016; 2101-2105

54. Müller a et al. *Involvement of chemokine receptors in breast cancer metastasis*. Nature. 2001;410:50-56.
55. Yan et al. *Understanding patterns of brain metastasis in triple-negative breast cancer and exploring potential therapeutic targets*. Oncotargets and Therapy. 2021

